GLP-1 Medication Side Effects (Canada)
Adverse reactions, warnings, and special-population considerations sourced directly from Health Canada-approved product monographs. Select a medication below.
Ozempic
semaglutide
Novo Nordisk
OZEMPIC® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control.
View side effects →
Wegovy
semaglutide
Novo Nordisk
WEGOVY® is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
View side effects →
Mounjaro
tirzepatide
Eli Lilly
MOUNJARO (tirzepatide injection) is indicated for once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus.
View side effects →
Zepbound
tirzepatide
Eli Lilly
ZEPBOUND (tirzepatide injection) is indicated for once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbid condition.
View side effects →